Long-term treatment with oral enoximone for chronic congestive heart failure: the European experience.

[1]  K. Haegele,et al.  Electrophysiological effects of intravenous MDL 17.043. , 1986, International journal of cardiology.

[2]  R. Scognamiglio,et al.  Variability of positive inotropic response to acute amrinone administration in chronic cardiac failure. , 1986, European heart journal.

[3]  J. Shaver,et al.  Noninvasive evaluation of systolic and diastolic function in severe congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.

[4]  A. Hakki,et al.  Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.

[5]  J. S. Janicki,et al.  Effects of new inotropic agents on exercise performance. , 1986, Circulation.

[6]  R. Lang,et al.  Milrinone versus dobutamine: contribution of altered myocardial mechanics and augmented inotropic state to improved left ventricular performance. , 1986, Circulation.

[7]  P. Reddy,et al.  Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. , 1986, Circulation.

[8]  E. Sonnenblick,et al.  Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance. , 1986, Circulation.

[9]  A. Goldberg,et al.  Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure. , 1986, The American journal of cardiology.

[10]  B. Massie,et al.  Hemodynamic changes after meals and placebo treatment in chronic congestive heart failure. , 1986, The American journal of cardiology.

[11]  T. LeJemtel,et al.  Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure. , 1985, American heart journal.

[12]  S. Rubin,et al.  MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure. , 1985, Journal of the American College of Cardiology.

[13]  P. Reddy,et al.  MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. , 1985, Journal of the American College of Cardiology.

[14]  F. Shellock,et al.  Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. , 1985, American heart journal.

[15]  B. Massie,et al.  Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. , 1985, Circulation.

[16]  F. Shellock,et al.  Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. , 1985, Circulation.

[17]  W. M. Smith.  Epidemiology of congestive heart failure. , 1985, The American journal of cardiology.

[18]  F. Shellock,et al.  Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure. , 1985, American heart journal.

[19]  W. Parmley,et al.  Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure. , 1984, American heart journal.

[20]  W. Parmley,et al.  Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. , 1984, Journal of the American College of Cardiology.

[21]  J. F. Lang,et al.  Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. , 1984, The American journal of cardiology.

[22]  M. Crawford,et al.  Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. , 1984, The American journal of cardiology.

[23]  T. Meinertz,et al.  Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. , 1984, The American journal of cardiology.

[24]  M. Packer,et al.  Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. , 1983, Journal of the American College of Cardiology.

[25]  E. Braunwald,et al.  Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. , 1983, The New England journal of medicine.

[26]  R. Magorien,et al.  Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[27]  P. Reddy,et al.  The Acute Hemodynamic Effects of a New Agent, MDL 17,043, in the Treatment of Congestive Heart Failure , 1983, Circulation.

[28]  J. Cohn,et al.  Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[29]  J. Cohn,et al.  Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. , 1982, American heart journal.

[30]  W. Voelker,et al.  Hemodynamic Effects of Prenalterol in Patients with Ischemic Heart Disease and Congestive Cardiomyopathy , 1982, Circulation.

[31]  R. C. Dage,et al.  Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043 , 1982, Journal of cardiovascular pharmacology.

[32]  C. P. Hsieh,et al.  Cardiovascular Properties of a New Cardiotonic Agent: MDL 17,043 (1,3‐Dihydro-4‐methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol‐2-one) , 1982, Journal of cardiovascular pharmacology.

[33]  K. Borow,et al.  Sensitivity of End‐systolic Pressure‐Dimension and Pressure‐Volume Relations to the Inotropic State in Humans , 1982, Circulation.

[34]  J. S. Janicki,et al.  Cardiotonic agents in the management of chronic cardiac failure. , 1982, American heart journal.

[35]  E. Sonnenblick,et al.  Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. , 1982, The American journal of medicine.

[36]  V. Fuster,et al.  The natural history of idiopathic dilated cardiomyopathy. , 1981, The American journal of cardiology.

[37]  R. Magorien,et al.  Reproducibility of echocardiography in chronic congestive heart failure , 1980, Journal of clinical ultrasound : JCU.

[38]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[39]  A. Weissler,et al.  Systolic Time Intervals in Heart Failure in Man , 1968, Circulation.